已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

滤泡性淋巴瘤 医学 耐火材料(行星科学) 队列 卵泡期 肿瘤科 内科学 淋巴瘤 CD20 生物 天体生物学
作者
Kim Linton,Umberto Vitolo,Wojciech Jurczak,Pieternella J. Lugtenburg,Emmanuel Gyan,Anna Sureda,Jacob Haaber Christensen,Brian T. Hess,Hervé Tilly,Raúl Córdoba,David John Lewis,Craig Okada,Martin Hutchings,Michael Roost Clausen,Juan‐Manuel Sancho,Tara Cochrane,Sirpa Leppä,Martine E.D. Chamuleau,Diana Gernhardt,Işıl Altıntaş
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:11 (8): e593-e605 被引量:41
标识
DOI:10.1016/s2352-3026(24)00166-2
摘要

Background A standard of care and optimal duration of therapy have not been established for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was to evaluate epcoritamab, a novel CD3 × CD20 bispecific antibody, in the third-line and later setting of follicular lymphoma. Methods EPCORE NHL-1 is a multicohort, single-arm, phase 1–2 trial conducted at 88 sites across 15 countries. Here, we report the primary analysis of patients with relapsed or refractory follicular lymphoma in the phase 2 part of the trial, which included the pivotal (dose expansion) cohort and the cycle 1 optimisation cohort. Eligible patients were aged 18 years or older, had relapsed or refractory CD20+ follicular lymphoma (grade 1–3A), an Eastern Cooperative Oncology Group performance status of up to 2, and had received at least two previous lines of therapy (including an anti-CD20 monoclonal antibody and an alkylating agent or lenalidomide). Patients were treated with subcutaneous epcoritamab 48 mg in 28-day cycles: weekly in cycles 1–3, biweekly in cycles 4–9, and every 4 weeks until disease progression or unacceptable toxicity. To mitigate the risk and severity of cytokine release syndrome, in the pivotal cohort, cycle 1 consisted of a step-up dosing regimen of a 0·16-mg priming dose on day 1 and a 0·80-mg intermediate dose on day 8, followed by subsequent 48-mg full doses and prophylactic prednisolone 100 mg; in the cycle 1 optimisation cohort, a second intermediate dose of 3 mg on day 15, adequate hydration, and prophylactic dexamethasone 15 mg were evaluated during cycle 1 to further reduce risk and severity of cytokine release syndrome. Primary endpoints were independently reviewed overall response rate for the pivotal cohort and the proportion of patients with grade 2 or worse and any-grade cytokine release syndrome for the cycle 1 optimisation cohort. Analyses were done in all enrolled patients who had received at least one dose of epcoritamab. This study is registered with ClinicalTrials.gov, NCT03625037, and is ongoing. Findings Between June 19, 2020, and April 21, 2023, 128 patients (median age 65 years [IQR 55–72]; 49 [38%] female and 79 [62%] male) were enrolled and treated in the pivotal cohort (median follow-up 17·4 months [IQR 9·1–20·9]). The overall response rate was 82·0% (105 of 128 patients; 95% CI 74·3–88·3), with a complete response rate of 62·5% (80 of 128; 95% CI 53·5–70·9). The most common grade 3–4 treatment-emergent adverse event was neutropenia in 32 (25%) of 128 patients. Grade 1–2 cytokine release syndrome was reported in 83 (65%) of 128 patients; grade 3 cytokine release syndrome was reported in two (2%). Immune effector cell-associated neurotoxicity syndrome was reported in eight (6%) of 128 patients (five [4%] grade 1; three [2%] grade 2). Between Oct 25, 2022, and Jan 8, 2024, 86 patients (median age 64 years [55–71]; 37 [43%] female and 49 [57%] male) were enrolled and treated in the cycle 1 optimisation cohort. The incidence of cytokine release syndrome was 49% (42 of 86 patients; eight [9%] grade 2; none of grade 3 or worse), with no reported immune effector cell-associated neurotoxicity syndrome. Interpretation Epcoritamab monotherapy showed clinically meaningful activity in patients with multiply relapsed or refractory follicular lymphoma, and had a manageable safety profile. Funding Genmab and AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丘比特应助Ahiterin采纳,获得80
1秒前
1秒前
Mars_1108发布了新的文献求助10
2秒前
2秒前
余子健完成签到 ,获得积分10
3秒前
rita4616发布了新的文献求助10
4秒前
djam发布了新的文献求助10
4秒前
5秒前
余子健关注了科研通微信公众号
5秒前
6秒前
有魅力强炫完成签到 ,获得积分10
8秒前
9秒前
choo发布了新的文献求助10
9秒前
芯之痕发布了新的文献求助10
10秒前
Candy2024完成签到 ,获得积分10
10秒前
俏皮的白柏完成签到,获得积分10
11秒前
liu完成签到 ,获得积分10
14秒前
wendy完成签到,获得积分10
14秒前
英姑应助科研蜗牛采纳,获得10
14秒前
14秒前
18秒前
MethaForbid发布了新的文献求助10
19秒前
黄晶晶关注了科研通微信公众号
22秒前
YamDaamCaa应助多发论文采纳,获得30
22秒前
23秒前
25秒前
阿司匹林发布了新的文献求助10
25秒前
27秒前
suki发布了新的文献求助10
27秒前
科研通AI5应助DDD采纳,获得10
28秒前
28秒前
DrYang发布了新的文献求助10
29秒前
29秒前
32秒前
Vi完成签到 ,获得积分10
32秒前
小汤发布了新的文献求助10
33秒前
fanssw发布了新的文献求助10
33秒前
量子星尘发布了新的文献求助10
33秒前
34秒前
刘坦苇完成签到,获得积分10
34秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976512
求助须知:如何正确求助?哪些是违规求助? 3520548
关于积分的说明 11203949
捐赠科研通 3257210
什么是DOI,文献DOI怎么找? 1798648
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806555